potential treatment for Alzheimer’s. Also in 2014, the company secured approval for Movantik (naloxegol) in the U.S. and Moventig in the EU for the treatment of opioid-induced constipation. Movantik/Moventig approval Movantik/Moventig, which was approved in the U.S. in September 2014 and in the EU in December 2014, is the orally administered, once daily peripherally-acting mu-opioid receptor antagonist (PAMORA) to be approved for the treatment of opioid induced constipation (OIC) in adult patients who have had an inadequate response to laxatives. Movantik/Moventig acts directly on the mu-opioid receptors in the gut, which cause OIC when opioids are used, and constitutes an important and novel option for opioid users. Movantik/Moventig was developed using Nektar Therapeutics’ oral small molecule polymer conjugate technology as part of a 2009 licence agreement with Nektar Therapeutics. In 2014, the company signed an agreement with Lilly for the joint development and commercialisation of AZD3293, its oral beta secretase cleaving enzyme (BACE) inhibitor being developed as a potential treatment for Alzheimer’s disease. The company has collaborations with the University of Cambridge (focusing on advancing research and development in neurodegenerative diseases), the Karolinska Institutet (Sweden), the Banner Alzheimer’s Institute (US), the National Institute of Radiological Sciences (Japan), Vanderbilt University (US) (focusing on psychosis and other neuropsychiatric symptoms associated with major brain diseases, such as Alzheimer’s disease and schizophrenia), an alliance of several academic centres (known as ‘A5’), and Tufts University (US) (focusing on brain diseases and disorders, including Alzheimer’s disease, Parkinson’s disease and autism spectrum disorders). The company also joined the Medical Research Council Dementias Platform UK (DPUK), a large public-private partnership to accelerate and share dementias research. The company’s anaesthesia portfolio consists of various compounds, including an intravenous general anaesthetic/sedative and local anaesthetics available in different formulations, including injectables, creams, gels, sprays and suppositories. Biologics are an emerging treatment for pain control and the company is exploring treatments in focused pain areas where patients can be selected based on symptomatic characteristics. The company is developing AZD5213, a Phase II histamine-3 receptor antagonist for neuropathic pain. Gastrointestinal Marketed Products Entocort (budesonide) is a locally-acting corticosteroid used to treat inflammatory bowel disease. Losec/Prilosec (omeprazole) is used for the short- and long-term treatment of acid-related diseases. Nexium (esomeprazole magnesium) is a proton pump inhibitor used to treat acid-related diseases. Significant Events In March 2015, AstraZeneca has entered into an alliance with Singapore's Agency for Science, Technology and Research, National University Heart Centre, Singapore (NUHCS), and the National University of Singapore. In March 2015, AstraZeneca has announced a co-commercialization agreement with Daiichi Sankyo Inc. for MOVANTIK, a once-daily oral peripherally-acting mu-opioid receptor antagonist, or PAMORA, for the treatment of opioid-induced constipation, or OIC, in adults with chronic non-cancer pain, in the U.S. Myriad Genetics has expanded diagnostic collaboration with AstraZeneca under which its BRACAnalysis CDx test would e used to identify which patients with metastatic pancreatic cancer may respond to treatment with AstraZeneca's Lynparza. In April 2015, AstraZeneca has entered into five-year research collaboration with the Harvard Stem Cell Institute, or HSCI, to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca's compound library in the search for new treatments for diabetes. History The company was founded 1992. It was incorporated in England and Wales in 1992 under the Companies Act 1985. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in 1999.
astrazeneca plc-spons adr (AZN:New York)
2 Kingdom Street
London, W2 6BD
Phone: 44 20 7604 8000
Fax: 44 20 7604 8151www.astrazeneca.com
|AbbVie Inc||$62.29 USD||-0.30|
|BASF SE||€89.06 EUR||-2.39|
|Biogen Inc||$419.44 USD||-9.21|
|Celgene Corp||$113.47 USD||-2.89|
|Eli Lilly & Co||$72.47 USD||-1.02|
|View Industry Companies|
Sponsored Financial Commentaries
To contact ASTRAZENECA PLC-SPONS ADR, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.